Prevalence of T3 thyrotoxicosis and it’s management in new onset thyrotoxicosis patients: a prospective observational study

Shailendra Kumar Singh; Rina Singh; Sonam Bedi; Arun Kumar Pandey; Alankar Tiwari; Pradeep Kumar Rai

doi:10.18203/2349-3933.ijam20243812

Authors

Shailendra Kumar Singh Department of Endocrine, Endocrine Clinic, Varanasi, UP, India https://orcid.org/0000-0001-8840-5691
Rina Singh Department of Endocrine, Endocrine Clinic, Varanasi, UP, India
Sonam Bedi Department of Community Medicine, GMCH, Udaipur, Rajasthan, India
Arun Kumar Pandey Department of Endocrine, LEDTC, Gomtinagar, Lucknow, UP, India
Alankar Tiwari Department of Endocrine, DECSC, Varanasi, UP, India
Pradeep Kumar Rai Department of Nephrology, Opal Hospital, Varanasi, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20243812

Keywords:

T3 toxicosis, Grave's disease, Carbimazole, Thyrotoxicosis

Abstract

Background: T3 toxicosis is a subtype of thyrotoxicosis where total triiodothyronine (TT3) level is high but total thyroxine (TT4) level is normal in presence of suppressed thyroid stimulating hormone (TSH). Accurate and rapid diagnosis is crucial in management of T3 toxicosis.

Methods: In this prospective observational study from India, newly diagnosed thyrotoxicosis patients were enrolled. T3 toxicosis patients were diagnosed based on diagnostic criteria. T3 toxicosis patients were randomized into two arms, based on dose of carbimazole (CBZ) used for treatment. All patients are following up for 12-14 weeks.

Results: Prevalence of T3 toxicosis was 8.5% in this study. 75% were diagnosed as Grave’s disease (GD) and 25% were diagnosed as toxic nodular goiter (TNG). Low dose (5 mg/day) of CBZ is safer and more effective than higher dose (20 mg/day).

Conclusion: Present study suggests that a significant number of patients with thyrotoxicosis are suffering from T3 toxicosis. So, for correct diagnosis of thyrotoxicosis one should investigate for TT3, TT4 and TSH, otherwise we can misdiagnose the T3 toxicosis as subclinical thyrotoxicosis (SCT). Majority of T3 toxicosis patients are diagnosed as GD. Low dose of CBZ is very much effective and safe in these patients. We recommend low dose of CBZ in all patients with T3 toxicosis.

Metrics

Metrics Loading ...

References

Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155-66.

Carlé A, Andersen SL, Boelaert K, Laurberg P, Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy. Eur J Endocr. 2017;176(6):325-7.

Singh SK, Singh R, Singh A. Prevalence of thyroid disorder (TD) in newly diagnosed type 2 diabetes mellitus patients a cross-sectional study. J Assoc Physicians India. 2021;69(10):11-22.

Blick C, Nguyen M, Jialal I. Thyrotoxicosis. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books. Accessed on 12 August 2024.

Sterling K, Refetoff S, Selenkow HA. T3 Thyrotoxicosis: Thyrotoxicosis Due to Elevated Serum Triiodothyronine Levels. JAMA. 1970;213(4):571–5.

Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-421.

Sriphrapradang C, Bhasipol A. Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. Ann Med Surg (Lond). 2016;10:69-72.

Snabboon T, Sridama V, Sunthornyothin S, Suwanwalaikorn S, Vongthavaravat V. A more appropriate algorithm of thyroid function test in diagnosis of hyperthyroidism for Thai patients. J Med Assoc Thai. 2004;2:19-21

Bellabarba D, Bénard B, Langlois M. Pattern of serum thyroxine, triiodothyronine and thyrotrophin after treatment of thyrotoxicosis. Clin Endocrinol (Oxf). 1972;1(4):345-53.

Hollander CS, Mitsuma T, Shenkman L, Stevenson C, Pineda G, Silva E. T3 toxicosis in an iodine-deficient area. Lancet. 1972;2(7790):1276-8.

Kopp P. Thyrotoxicosis of other etiologies. editors. Endotext. South Dartmouth (MA). 2000. Available at: https://www.ncbi.nlm.nih.gov. Accessed on 14 August 2024.

Hollander CS, Mitsuma T, Nihei N, Shenkman L, Burday SZ, Blum M. Clinical and laboratory observations in cases of triiodothyronine toxicosis confirmed by radioimmunoassay. Lancet. 1972;1(7751):609-11.

Figge J, Leinung M, Goodman AD, Izquierdo R, Mydosh T, Gates S, Line B, Lee DW. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med. 1994;96(3):229-34.

Salvatore D, Tu H, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest. 1996;98(4):962-8.

Obregon MJ, Escobar del Rey F, Morreale de Escobar G. The effects of iodine deficiency on thyroid hormone deiodination. Thyroid. 2005;15(8):917-29.

Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474-81.

Singh SK, Singh R, Singh SK, Iquebal MA, Jaiswal S, Rai PK. Aetiological sub-classification of thyrotoxicosis and relevance of TT3/TT4 ratio in sub-classification of patients with thyrotoxicosis; an Indian cross-sectional study. Int J Adv Med. 2023;10:830-5.

Singh SK, Singh R, Singh SK, Pandey AK, Jaiswal S, Rai PK. Thyroid dysfunction in India: what is different. Int J Adv Med. 2024;11:286-90.

Singh SK, Singh R, Singh SK, Iquebal MA, Jaiswal S, Rai PK. Risk of progression to overt hypothyroidism in Indian patients with subclinical hypothyroidism: a prospective observational study. Int J Adv Med. 2022;9:1183-7

Andersson M, Takkouche B, Egli I, Allen HE, de Benoist B. Current global iodine status and progress over the last decade towards the elimination of iodine deficiency. Bull World Health Organ. 2005;83(7):518-25.

Shenkman L, Mitsuma T, Blum M, Hollander CS. Recurrent hyperthyroidism presenting as triiodothyronine toxicosis. Ann Intern Med. 1972;77(3):410-3.

Jansson R, Dahlberg PA, Johansson H, Lindström B. Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab. 1983;57(1):129-32.

Cooper DS. Antithyroid drugs. N Engl J Med. 1984 Nov 22;311(21):1353-62.